Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
swbCTkQNntrAYjRP
